B7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART) in Recurrent Glioblastoma Multiforme

  • STATUS
    Recruiting
  • End date
    Aug 8, 2025
  • participants needed
    39
  • sponsor
    Crystal Mackall, MD
Updated on 4 October 2022

Summary

This is an open label, non-randomized, single site Phase I study to test the manufacturing feasibility and safety of locoregional (LR) administration of B7-H3CART into the central nervous system of adult subjects with recurrent IDH wild-type GBM using a standard 3+3 dose escalation design.

Details
Condition Brain and Nervous System
Treatment B7-H3CART
Clinical Study IdentifierNCT05474378
SponsorCrystal Mackall, MD
Last Modified on4 October 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Histologically confirmed high grade (WHO Grade IV) glioma including but not limited to glioblastoma, gliosarcoma, glioblastoma with oligodendroglial features, glioblastoma with PNET features, tested as IDH wild-type, as per revised WHO 2021 criteria. Patients must also have evidence of tumor recurrence/progression by MRI (RANO criteria) after standard front-line therapy. b. First recurrence or progressive disease after a standard line therapy
Resectable disease: Resection is being considered as part of the standard of care for the patient and it is thought that it is feasible that a majority of contrast-enhancing tumor mass/signal can be resected
Patients must be between the ages of 18 and 75 years old (inclusive)
Karnofsky Performance score ≥ 60
Use of steroids must be limited to ≤ 4 mg of decadron daily
Adequate organ function at time of screening visit including
Hgb ≥ 12 g/dL (male) or ≥ 11.5 g/dL (females)
ANC ≥ 1500/uL
Platelets ≥ 100,000/uL
Absolute lymphocyte count ≥150/uL
Serum Creatinine ≤ 1.5mg/dl; Cr clearance should be ≥ 50 mL/min
Serum AST and ALT ≤ 3x ULN (Grade 1)
Total Bilirubin ≤ 1.5 X ULN
PT or PTT ≤ 1.25 X ULN
Cardiac ejection fraction ≥45% without signs of physiologically significant pericardial effusion or clinically significant ECG findings
Baseline oxygen saturation > 92% on room air
Subjects of child-bearing or child-fathering potential must be willing to use an
effective method of contraception (hormonal or two barrier methods) while on
study and for at least 4 months following the last CAR T cell infusion or as
long as B7-H3CART are detectable in peripheral blood or CSF
All female subjects of childbearing age must have a negative blood or urine pregnancy test
Ability to understand and willingness to sign a written informed consent document
Must be willing and able to comply with procedures, return visits and evaluations at Stanford Health Care while on this protocol
Prior Therapy
At least 6 weeks following completion of front-line radiation therapy
At least 3 weeks post chemotherapy or 5 half-lives, whichever is shorter must have elapsed since any prior systemic therapy, except for systemic inhibitory/stimulatory immune checkpoint therapy, which requires 5 half-lives
At least 4 weeks from bevacizumab treatment, which can be used only for radiation necrosis or pseudo-progression
Prior cytotoxic chemotherapy, radiation, or other anticancer therapies including investigational agents discontinued at least 4 weeks prior to Day 1 of treatment
Toxicities due to prior therapy must be stable and recovered to ≤ Grade 1 (except for clinically non-significant toxicities such as alopecia)

Exclusion Criteria

Pregnant or patients who are breastfeeding
Prior or concurrent treatment with Avastin (bevacizumab) for the purposes of recurrent disease. Avastin (bevacizumab) may have been used for radiation necrosis
Prior exposure to chimeric antigen receptor (CAR) based therapies
Known sensitivity or allergy to any agents/reagents used in this study
Patients receiving anticoagulation therapy
Prior malignancy except previously diagnosed and definitively treated more than 3 years prior to trial or whose prognosis is deemed good enough to not warrant surveillance
Clinical evidence of significant increased intracranial pressure (i.e. impending herniation) or uncontrolled seizures
Presence of fungal, bacterial, viral, or other infection that is uncontrolled or requiring IV antimicrobials for management. Simple UTI and uncomplicated bacterial pharyngitis are permitted if responding to active treatment
Known history of infection with HIV or hepatitis B (HBsAg positive) or hepatitis C virus (anti-HCV positive). A history of hepatitis B or hepatitis C is permitted if the viral load is undetectable per quantitative PCR and/or nucleic acid testing
Primary immunodeficiency or history of autoimmune disease (e.g. Crohn's, rheumatoid arthritis, systemic lupus) resulting in end organ injury or requiring systemic immunosuppression/systemic disease modifying agents within the last 2 years
Significant medical diseases or conditions, including poorly controlled conditions: i.e. hypertension, cardiovascular disease, diabetes mellitus, chronic obstructive pulmonary disease, pulmonary fibrosis, inflammatory disorders, immunodeficiency (e.g., HIV infection), immune compromised for reasons other than malignancy (e.g., chronic corticosteroid therapy or other immunosuppressive therapy), renal failure including patients requiring dialysis, liver dysfunction, second malignancy (except treated basal cell or localized squamous cell skin carcinomas), or active infection
History of bone marrow or stem cell transplantation
In the investigator's judgment, the subject is unlikely to complete all protocolrequired study visits or procedures, including follow-up visits, or comply with the study requirements for participation
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note